Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells

J Labrecque, A Fargin, M Bouvier, P Chidiac and M Dennis

BioSignal Inc., Montreal, Quebec, Canada.

The activities of serotonergic antagonists as inverse agonists at the rat 5-hydroxytryptamine (5-HT)2C serotonin receptor were compared with their potencies in promoting receptor "down-regulation," after expression of the recombinant receptor in the baculovirus/Sf9 insect cell system. Baculovirus expression yielded high levels of 5-HT2C receptors (up to 10(6) receptors/cell), which were functionally coupled to polyphosphoinositide turnover in Sf9 cells through a pertussis toxin- insensitive pathway. The expressed receptor exhibited spontaneous activation of inositol phosphate production, which was inhibited in a dose-dependent manner by serotonergic antagonists, consistent with inverse agonist activity. The potencies of antagonists as inverse agonists correlated with their respective binding affinities determined in competition binding studies with membrane preparations. The maximal inhibition of spontaneous activity ranged from 32% inhibition for mianserin to no effect for spiroxatrine, indicating that antagonists differ in their intrinsic inverse efficacies. Antagonist treatment of intact Sf9 cells or membranes containing the 5-HT2C receptor, followed by washout of residual drug, resulted in a decrease (up to 90%) in the number of binding sites for [3H]mesulergine and [3H]5-HT, with no change in the affinity for [3H]mesulergine. The decrease in binding was irreversible, was not due to the presence of residual antagonist, and was not observed after treatment with agonists. This effect of antagonists in membranes was dose dependent, but the rank order of potency was clearly different from that for inverse agonist activity, indicating that the two effects reflect distinct actions of antagonists at the 5-HT2C receptor. The relative abilities of antagonists to produce loss of binding showed a good correlation with their reported abilities to down-regulate 5-HT2 receptors in vivo after chronic treatment, suggesting that these actions reflect the same underlying process.

Volume 48, Issue 1, pp. 150-159, 07/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				T. Kenakin Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism Mol. Pharmacol., January 1, 2004; 65(1): 2 - 11. [Abstract] [Full Text] [PDF]

				C. Schroeder, A. Breit, H. Boning, J. Dedio, L. Gera, J. Stewart, and W. Muller-Esterl Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems: Changes in amino-terminal portion of human B2 receptor selectively increase efficacy of synthetic ligand HOE 140 but not of cognate ligand bradykinin Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H1924 - H1932. [Abstract] [Full Text] [PDF]

				M. Azzi, G. Pineyro, S. Pontier, S. Parent, H. Ansanay, and M. Bouvier Allosteric Effects of G Protein Overexpression on the Binding of beta -Adrenergic Ligands with Distinct Inverse Efficacies Mol. Pharmacol., November 1, 2001; 60(5): 999 - 1007. [Abstract] [Full Text] [PDF]

				L. Rauser, J. E. Savage, H. Y. Meltzer, and B. L. Roth Inverse Agonist Actions of Typical and Atypical Antipsychotic Drugs at the Human 5-Hydroxytryptamine2C Receptor J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 83 - 89. [Abstract] [Full Text] [PDF]

				G. Pineyro, M. Azzi, A. De Lean, P. Schiller, and M. Bouvier Short-Term Inverse-Agonist Treatment Induces Reciprocal Changes in delta -Opioid Agonist and Inverse-Agonist Binding Capacity Mol. Pharmacol., October 1, 2001; 60(4): 816 - 827. [Abstract] [Full Text] [PDF]

				P. A. Zaki, D. E. Keith Jr., J. B. Thomas, F. I. Carroll, and C. J. Evans Agonist-, Antagonist-, and Inverse Agonist-Regulated Trafficking of the delta -Opioid Receptor Correlates with, but Does Not Require, G Protein Activation J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1015 - 1020. [Abstract] [Full Text]

				K. A. Berg, B. D. Stout, J. D. Cropper, S. Maayani, and W. P. Clarke Novel Actions of Inverse Agonists on 5-HT2C Receptor Systems Mol. Pharmacol., May 1, 1999; 55(5): 863 - 872. [Abstract] [Full Text]

				M. Rinaldi-Carmona, A. Le Duigou, D. Oustric, F. Barth, M. Bouaboula, P. Carayon, P. Casellas, and G. Le Fur Modulation of CB1 Cannabinoid Receptor Functions after a Long-Term Exposure to Agonist or Inverse Agonist in the Chinese Hamster Ovary Cell Expression System J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1038 - 1047. [Abstract] [Full Text]

				A. A. Simen and R. J. Miller Structural Features Determining Differential Receptor Regulation of Neuronal Ca Channels J. Neurosci., May 15, 1998; 18(10): 3689 - 3698. [Abstract] [Full Text] [PDF]

				A. J. Barr and D. R. Manning Agonist-independent Activation of Gz by the 5-Hydroxytryptamine1A Receptor Co-expressed in Spodoptera frugiperda Cells. DISTINGUISHING INVERSE AGONISTS FROM NEUTRAL ANTAGONISTS J. Biol. Chem., December 26, 1997; 272(52): 32979 - 32987. [Abstract] [Full Text] [PDF]

				M. Bouaboula, S. Perrachon, L. Milligan, X. Canat, M. Rinaldi-Carmona, M. Portier, F. Barth, B. Calandra, F. Pecceu, J. Lupker, et al. A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1. EVIDENCE FOR A NEW MODEL OF RECEPTOR/LIGAND INTERACTIONS J. Biol. Chem., August 29, 1997; 272(35): 22330 - 22339. [Abstract] [Full Text] [PDF]

				A. Newman-Tancredi, V. Audinot, C. Chaput, and L.V. a. M. J. Millan [35S]Guanosine-5'-O-(3-thio)triphosphate Binding as a Measure of Efficacy at Human Recombinant Dopamine D4.4 Receptors: Actions of Antiparkinsonian and Antipsychotic Agents J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 181 - 191. [Abstract] [Full Text]

				B. F. Roettger, D. Ghanekar, R. Rao, C. Toledo, J. Yingling, D. Pinon, and L. J. Miller Antagonist-Stimulated Internalization of the G Protein-Coupled Cholecystokinin Receptor Mol. Pharmacol., March 1, 1997; 51(3): 357 - 362. [Abstract] [Full Text] [PDF]